KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Change in Receivables (2017 - 2025)

Historic Change in Receivables for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to -$63000.0.

  • Aquestive Therapeutics' Change in Receivables fell 10169.63% to -$63000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 8603.2%. This contributed to the annual value of -$1.1 million for FY2024, which is 13560.04% down from last year.
  • Aquestive Therapeutics' Change in Receivables amounted to -$63000.0 in Q3 2025, which was down 10169.63% from $1.3 million recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' Change in Receivables peaked at $7.7 million during Q1 2022, and registered a low of -$8.2 million during Q3 2022.
  • Its 5-year average for Change in Receivables is $231210.5, with a median of -$63000.0 in 2025.
  • In the last 5 years, Aquestive Therapeutics' Change in Receivables crashed by 213269.23% in 2024 and then surged by 222857.14% in 2025.
  • Aquestive Therapeutics' Change in Receivables (Quarter) stood at -$1.4 million in 2021, then crashed by 343.92% to -$6.1 million in 2022, then soared by 98.29% to -$104000.0 in 2023, then plummeted by 2132.69% to -$2.3 million in 2024, then soared by 97.29% to -$63000.0 in 2025.
  • Its last three reported values are -$63000.0 in Q3 2025, $1.3 million for Q2 2025, and $3.1 million during Q1 2025.